Status:
UNKNOWN
Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma
Lead Sponsor:
Zhang Dazhi,MD
Collaborating Sponsors:
Chongqing Three Gorges Central Hospital
The Affiliated Hospital Of Southwest Medical University
Conditions:
Time
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to explore whether there is difference in the incidence rate and incidence rate of HCC in patients with chronic hepatitis B who are screened for high risk of liver cancer. Whether the ...
Detailed Description
This study is a multicenter, prospective clinical study. Including the Second Affiliated Hospital of Chongqing Medical University, the Third Affiliated Hospital of Chongqing Medical University, the Fi...
Eligibility Criteria
Inclusion
- Willing and able to sign informed consent
- Male or female, 18 ≤ age≤ 75
- The diagnosis was in accordance with the 2019 guidelines for the diagnosis and treatment of chronic hepatitis B and received anti HBV treatment for 48 weeks;
- Imaging examination showed liver nodules or space occupying lesions (any imaging examination of abdominal color Doppler ultrasound, CT and MRI), and imaging examination could not determine the benign and malignant of the lesions
- The estimated survival time is more than half a year
- Peripheral blood cfdna gene screening is high risk
- Full capacity for civil conduct
Exclusion
- Primary liver cancer was diagnosed or supported by the following evidence: elevated alpha fetoprotein (AFP \> 100ng / ml) or liver imaging showed clear liver cancer nodules in the liver
- Have a history of malignant tumors within 5 years before screening, except for specific cancers cured by surgical resection (such as basal cell skin cancer, etc.)
- Current or previous history of major diseases that may interfere with personal treatment, evaluation or compliance. Major diseases are 25 major diseases specified by the CIRC
- Combined with HCV, HIV, HDV or other infectious diseases
- Severe lung disease, severe heart disease or genetic metabolic disease
- Psychiatric hospitalization, attempted suicide and / or temporary disability due to mental illness in the past 5 years
- Combined with autoimmune liver disease, alcoholic liver disease and drug-induced liver injury
- Pregnant or lactating women
- The researcher believes that it is not suitable to participate in this experiment.
Key Trial Info
Start Date :
May 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05256459
Start Date
May 10 2022
End Date
December 15 2024
Last Update
May 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.